Arrowhead Pharmaceuticals (ARWR) Scheduled to Post Quarterly Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) will post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.58) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. The firm’s revenue was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 EPS. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Stock Up 3.1 %

Shares of NASDAQ:ARWR opened at $25.86 on Wednesday. The firm has a fifty day moving average of $26.21 and a two-hundred day moving average of $27.35. Arrowhead Pharmaceuticals has a 12-month low of $20.67 and a 12-month high of $39.83. The firm has a market capitalization of $3.21 billion, a P/E ratio of -6.08 and a beta of 0.94.

Analyst Ratings Changes

A number of analysts recently issued reports on ARWR shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday, June 20th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 23rd. The Goldman Sachs Group initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “neutral” rating and a $31.00 target price for the company. Finally, Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $43.25.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider Tracie Oliver sold 9,394 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the transaction, the insider now directly owns 127,107 shares of the company’s stock, valued at approximately $3,213,264.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.50% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.